IL1B and rheumatoid arthritis: As a typical anti-inflammatory drug, TP indirectly treated bone destruction in RA by inhibiting the levels of pro-inflammatory cytokines such as TNF-α and IL-1β and promoting the secretion of IL-10 and TGF-β1 derived from T cells (Xu et al., 2016).